Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Yeh, Celine [1 ]
Harrold, Emily [1 ]
Keane, Fergus [1 ]
Sinopoli, Jenna Cohen [1 ]
Foote, Michael Bonner [1 ]
Cercek, Andrea [1 ]
Yaeger, Rona [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3542
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.
    Sammons, Sarah
    Elliott, Andrew
    Force, Jeremy Meyer
    DeVito, Nicholas C.
    Marcom, Paul Kelly
    Swain, Sandra M.
    Tan, Antoinette R.
    Torres, Evanthia T. Roussos
    Zeng, Jia
    Khasraw, Mustafa
    Balko, Justin M.
    Korn, Wolfgang Michael
    Anders, Carey K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
    Saeed, Anwaar
    Barnett, Reagan
    Lou, Emil
    da Silva, Luciana Madeira
    Cho, May Thet
    Lieu, Christopher Hanyoung
    Fakih, Marwan
    Kopetz, Scott
    Loree, Jonathan M.
    Gholami, Sepideh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 249 - 249
  • [3] Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
    Ahmed, Jibran
    Das, Biswajit
    Shin, Sarah
    Chen, Alice
    CANCERS, 2023, 15 (24)
  • [4] Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms
    Padda, Sukhmani Kaur
    Aggarwal, Rahul Raj
    Ashok, Arya
    Mauer, Elizabeth
    Shirazi, Maryam
    Bergsland, Emily K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC)
    Amanam, I.
    Chao, J.
    Lim, D.
    Rahmanuddin, S.
    Schrock, A. B.
    Ali, S. M.
    Lau, C.
    Chevalier, D.
    Harris, E.
    Saluja, J.
    Wang, C.
    Fakih, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)
    Stahler, Arndt
    Stintzing, Sebastian
    von Einem, Jobst C.
    Westphalen, C. Benedikt
    Kraemer, Nicole
    Michl, Marlies
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Scheithauer, Werner
    Moehler, Markus
    Vehling-Kaiser, Ursula
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 48 - 48
  • [7] Impact of intratumor heterogeneity (ITH) on survival outcomes in patients with non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB-H)
    Fridland, Stanislav
    Kim, Hye Sung
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
    Salem, M. E.
    Puccini, A.
    Grothey, A.
    Xiu, J.
    Goldberg, R.
    Kim, E. S.
    Korn, W. M.
    Lenz, H-J.
    Raghavan, D.
    Marshall, J. L.
    Hall, M. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).
    Heinemann, Volker
    Kraemer, Nicole
    Buchner, Hannes
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmuller, Christian A.
    Kahl, Christoph
    Kullmann, Frank
    Moehler, Markus H.
    Scheithauer, Werner
    Held, Swantje
    Modest, Dominik Paul
    Neumann, Jens
    Jung, Andreas
    Kirchner, Thomas
    Stintzing, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
    Ellis, Haley
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Myer, Parvathi
    Lin, Douglas I.
    Panarelli, Nicole
    Fisher, Virginia
    Li, Gerald
    Huang, Richard S. P.
    Ross, Jeffrey S.
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 46 - 46
12345